Evaluating the Risk of Acute Kidney Injury and Mortality Associated with Concomitant Use of Vancomycin with Piperacillin/tazobactam or Meropenem in Critically Ill and Non-critically Ill Patients: a Systematic Review and Meta-analysis

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2025 Jan 8

PMID 39773457

Authors

Abdulmajeed M Alshehri

Majed S Al Yami

Atheer Aldairem

Lama Alfehaid

Abdulaali R Almutairi

Omar A Almohammed

Amal Mohammad Badawoud

Affiliations

Soon will be listed here.

Abstract

Background: There are conflicting findings regarding the risk of acute kidney injury (AKI) and mortality with vancomycin/piperacillin-tazobactam combination (VPT) and vancomycin/meropenem (VM). The aim of this meta-analysis was to compare the risk of AKI and mortality between VPT and VM.

Methods: Observational studies reporting the incidence of AKI and mortality in patients receiving VPT or VM between January 2017 and September 2024 were retrieved from PubMed, the Cochrane Library, and Web of Science. The primary outcome of the analysis was the risk of AKI, and the secondary outcomes were the mortality rate, need for renal replacement therapy (RRT), and hospital length of stay (LOS). This meta-analysis was conducted using a random-effects model to estimate the odds ratios (OR) and 95% confidence intervals (CI) for AKI, mortality, and RRT or mean difference and 95% CI for the LOS.

Results: Seventeen studies involving a total of 80,595 patients were included in the analysis. The odds of developing AKI were higher among patients who received the VPT versus those who received the VM combination (OR = 2.02; 95%CI 1.56-2.62). There were no differences between VPT and VM in the mortality and hospital length of stay; however, the odds of requiring RRT were higher among VPT group versus VM group (OR = 1.55; 95%CI 1.23-1.96).

Conclusion: The findings suggest that the use of VPT is associated with a higher risk of AKI compared to VM and highlight the need for cautious antibiotic selection and monitoring of renal function in patients receiving these combinations.

References

Mullins B, Kramer C, Bartel B, Catlin J, Gilder R . Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study. Ann Pharmacother. 2018; 52(7):639-644. DOI: 10.1177/1060028018757497. View

Al Yami M . Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. J Infect Public Health. 2017; 10(6):770-773. DOI: 10.1016/j.jiph.2016.11.007. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Balci C, Uzun O, Arici M, Hayran S, Yuce D, Unal S . Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?. Int J Antimicrob Agents. 2018; 52(2):180-184. DOI: 10.1016/j.ijantimicag.2018.03.024. View

Sawada A, Kawanishi K, Morikawa S, Nakano T, Kodama M, Mitobe M . Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review. BMC Nephrol. 2018; 19(1):72. PMC: 5872390. DOI: 10.1186/s12882-018-0845-1. View

Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D . Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11(2):R31. PMC: 2206446. DOI: 10.1186/cc5713. View

Wu D, Wang X, Li G, Chai X, Guo S, Zhou L . Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study. Expert Opin Drug Saf. 2024; :1-8. DOI: 10.1080/14740338.2024.2393263. View

Pais G, Liu J, Avedissian S, Hiner D, Xanthos T, Chalkias A . Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. 2020; 75(5):1228-1236. PMC: 8453375. DOI: 10.1093/jac/dkz563. View

Rungkitwattanakul D, Ives A, Harriott N, Pan-Chen S, Duong L . Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem. J Chemother. 2021; 34(2):103-109. DOI: 10.1080/1120009X.2021.1965334. View

10.

Blevins A, Lashinsky J, McCammon C, Kollef M, Micek S, Juang P . Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. Antimicrob Agents Chemother. 2019; 63(5). PMC: 6496064. DOI: 10.1128/AAC.02658-18. View

11.

Hayashi T, Watanabe Y, Kumano K, Kitayama R, Muratani T, Yasuda T . Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrob Agents Chemother. 1989; 33(4):513-8. PMC: 172470. DOI: 10.1128/AAC.33.4.513. View

12.

Liu K, Zhang Y, Xu X, Wu B, Ni J, Li T . Comparative Prevalence of Acute Kidney Injury in Chinese Patients Receiving Vancomycin with Concurrent β-Lactam Antibiotics: A Retrospective Cohort Study. Clin Ther. 2021; 43(10):e319-e351. DOI: 10.1016/j.clinthera.2021.08.008. View

13.

Aslan A, Pashayev T, Dag O, Akova M . Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury. Eur J Clin Microbiol Infect Dis. 2021; 40(9):1953-1961. DOI: 10.1007/s10096-021-04258-7. View

14.

Chang J, Pais G, Valdez K, Marianski S, Barreto E, Scheetz M . Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model. Antimicrob Agents Chemother. 2022; 66(3):e0213221. PMC: 8923227. DOI: 10.1128/aac.02132-21. View

15.

Levey A . Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron. 2021; 146(3):302-305. DOI: 10.1159/000516647. View

16.

Hayashi T, Watanabe Y, Kumano K, Kitayama R, Yasuda T, SAIKAWA I . Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals. Antimicrob Agents Chemother. 1988; 32(6):912-8. PMC: 172305. DOI: 10.1128/AAC.32.6.912. View

17.

Miano T, Hennessy S, Yang W, Dunn T, Weisman A, Oniyide O . Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med. 2022; 48(9):1144-1155. PMC: 9463324. DOI: 10.1007/s00134-022-06811-0. View

18.

Tanriver-Ayder E, Faes C, Van de Casteele T, McCann S, Macleod M . Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research. BMJ Open Sci. 2022; 5(1):e100074. PMC: 8647574. DOI: 10.1136/bmjos-2020-100074. View

19.

Lee J, Heintz B, Mosher H, Livorsi D, Egge J, Lund B . Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin. Clin Infect Dis. 2020; 73(7):e1579-e1586. DOI: 10.1093/cid/ciaa1902. View

20.

Contreiras C, Legal M, Lau T, Thalakada R, Shalansky S, Ensom M . Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. Can J Hosp Pharm. 2014; 67(2):126-32. PMC: 4006757. DOI: 10.4212/cjhp.v67i2.1340. View